NasdaqGM - Nasdaq Real Time Price USD

CareDx, Inc (CDNA)

23.63

-0.37

(-1.54%)

At close: January 10 at 4:00:02 PM EST

Implied Volatility Surging for CareDx (CDNA) Stock Options

Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.

Zacks 6 days ago

CDNA
-1.54%
High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has dropped 2.6%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of fluctuating performance and anticipated growth, identifying high growth tech stocks involves looking at companies with innovative technologies and strong potential for future expansion.

Simply Wall St. 10 days ago

MGTX

ACIU

CDNA
-1.54%
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., December 18, 2024--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Business Wire 25 days ago

CDNA
-1.54%
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial.

PR Newswire last month

CDNA
-1.54%
TCBP

TCBPW
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

BRISBANE, Calif., December 11, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial.

Business Wire last month

CDNA
-1.54%
Exploring High Growth Tech Stocks In The United States December 2024

The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. last month

CDNA
-1.54%
DVAX

FOLD
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?

Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks last month

CDNA
-1.54%
Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA)

Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities rose in the third quarter, driven by a dovish monetary policy shift from the Federal Reserve (Fed), and optimism around a soft economic landing. Class […]

Insider Monkey last month

CDNA
-1.54%
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know

The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

CDNA
-1.54%
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)

The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

CDNA
-1.54%
Are Medical Stocks Lagging CareDx (CDNA) This Year?

Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks last month

CDNA
-1.54%
DOCS
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal

The DOJ suggests that UNH's acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.

Zacks last month

UNH

AMED

THC
Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips

CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.

Zacks last month

CI

HUM

THC
CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif., November 12, 2024--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.

Business Wire last month

CDNA
-1.54%
Accelerated Testing Volume Lifted CareDx (CDNA) in Q3

Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund appreciated 13.55% (Institutional Shares), outperforming the 8.41% return for the Russell 2000 Growth Index. Year-to-date, the fund returned 9.50% compared to the index’s 13.22% […]

Insider Monkey 2 months ago

CDNA
-1.54%
CareDx Third Quarter 2024 Earnings: Beats Expectations

CareDx ( NASDAQ:CDNA ) Third Quarter 2024 Results Key Financial Results Revenue: US$82.9m (up 23% from 3Q 2023). Net...

Simply Wall St. 2 months ago

CDNA
-1.54%
Q3 2024 CareDx Inc Earnings Call

Q3 2024 CareDx Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

CDNA
-1.54%
CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

CareDx Inc (CDNA) reports a strong quarter with 23% revenue growth, positive adjusted EBITDA, and a solid cash position, while addressing future growth challenges and market uncertainties.

GuruFocus.com 2 months ago

CDNA
-1.54%
CareDx: Q3 Earnings Snapshot

CDNA) on Monday reported a loss of $7.4 million in its third quarter. On a per-share basis, the Brisbane, California-based company said it had a loss of 14 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 14 cents per share.

Associated Press Finance 2 months ago

CDNA
-1.54%
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

BRISBANE, Calif., November 04, 2024--CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024.

Business Wire 2 months ago

CDNA
-1.54%

Performance Overview

Return	CDNA	S&P 500
YTD	+11.57%	-1.35%
1-Year	+91.03%	+22.51%
3-Year	-39.52%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CareDx, Inc (CDNA)

Implied Volatility Surging for CareDx (CDNA) Stock Options

High Growth Tech Stocks in the United States

CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

Exploring High Growth Tech Stocks In The United States December 2024

Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?

Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA)

Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know

After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)

Are Medical Stocks Lagging CareDx (CDNA) This Year?

DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal

Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips

CareDx to Participate in Upcoming Investor Conferences

Accelerated Testing Volume Lifted CareDx (CDNA) in Q3

CareDx Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 CareDx Inc Earnings Call

CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

CareDx: Q3 Earnings Snapshot

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

Performance Overview